Evidence map›Paper›PMID 33187550›Full record

ArticleMolecular brain2020

Frequency and methylation status of selected retrotransposition competent L1 loci in amyotrophic lateral sclerosis.

Abigail L Savage, Ana Illera Lopez, Alfredo Iacoangeli, Vivien J Bubb, Bradley Smith, Claire Troakes, Nada Alahmady, Sulev Koks, Gerald G Schumann, Ammar Al-Chalabi and 1 more

Open access · goldAbstract read
In one paragraph

Article in Molecular brain, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. LINE-1 Retrotransposons and Amyotrophic Lateral Sclerosis.International journal of molecular sciences · 2026
    Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. TDP-43 Epigenetic Facets and Their Neurodegenerative Implications.International journal of molecular sciences · 2023
    Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 4 countries.

Abigail L SavageDepartment of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.
Ana Illera LopezDepartment of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.
Alfredo IacoangeliMaurice Wohl Clinical Neuroscience Institute, King's College London, London, UK.
Vivien J BubbDepartment of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.
Bradley SmithMaurice Wohl Clinical Neuroscience Institute, King's College London, London, UK.
Claire TroakesLondon Neurodegenerative Diseases Brain Bank, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, London, UK.
Nada AlahmadyMaurice Wohl Clinical Neuroscience Institute, King's College London, London, UK.
Sulev KoksPerron Institute for Neurological and Translational Science, Perth, WA, Australia.
Gerald G SchumannDivision of Medical Biotechnology, Paul-Ehrlich-Institut, Langen, Germany.
Ammar Al-ChalabiMaurice Wohl Clinical Neuroscience Institute, King's College London, London, UK.
John P QuinnDepartment of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK. JQUINN@LIV.AC.UK.ORCID 0000-0003-3551-7803
King's College London · GBUniversity of Liverpool · GBMurdoch University · AUPaul Ehrlich Institut · DE

Funding

Department of HealthMedical Research Council G0600974Medical Research Council MR/L016397/1Medical Research Council MR/L501529/1Medical Research Council MR/R024804/1Motor Neurone Disease Association ALCHALABI-DOBSON/APR14/829-791Motor Neurone Disease Association QUINN/APR15/843-791Motor Neurone Disease Association SMITH/APR16/847-791MRF_ MRF-060-0003-RG-SMITHWellcome Trust
6 · The paper itself

Abstract

Long interspersed element-1 (LINE-1/L1) is the only autonomous transposable element in the human genome that currently mobilises in both germline and somatic tissues. Recent studies have identified correlations between altered retrotransposon expression and the fatal neurodegenerative disease amyotrophic lateral sclerosis (ALS) in a subset of patients. The risk of an individual developing ALS is dependent on an interaction of genetic variants and subsequent modifiers during life. These modifiers could include environmental factors, which can lead to epigenetic and genomic changes, such as somatic mutations, occurring in the neuronal cells that degenerate as the disease develops. There are more than 1 million L1 copies in the human genome today, but only 80-100 L1 loci in the reference genome are considered to be retrotransposition-competent (RC) and an even smaller number of these RC-L1s loci are highly active. We hypothesise that RC-L1s could affect normal cellular function through their mutagenic potential conferred by their ability to retrotranspose in neuronal cells and through DNA damage caused by the endonuclease activity of the L1-encoded ORF2 protein. To investigate whether either an increase in the genomic burden of RC-L1s or epigenetic changes to RC-L1s altering their expression, could play a role in disease development, we chose a set of seven well characterised genomic RC-L1 loci that were reported earlier to be highly active in a cellular L1 retrotransposition reporter assay or serve as major source elements for germline and/or somatic retrotransposition events. Analysis of the insertion allele frequency of five polymorphic RC-L1s, out of the set of seven, for their presence or absence, did not identify an increased number individually or when combined in individuals with the disease. However, we did identify reduced levels of methylation of RC-L1s in the motor cortex of those individuals with both familial and sporadic ALS compared to control brains. The changes to the regulation of the loci encompassing these RC-L1s demonstrated tissue specificity and could be related to the disease process.

Indexed as

Genetic LociAmyotrophic Lateral SclerosisBrainCase-Control StudiesDNA MethylationGene FrequencyGenomic ImprintingHeterozygoteHumansLong Interspersed Nucleotide ElementsPolymorphism, Single NucleotidePromoter Regions, GeneticsnRNP Core ProteinssnRNP Core ProteinsAmyotrophic lateral sclerosisLINE-1MethylationRetrotransposition competent

Identifiers

PMID33187550
PMCPMC7666467
OpenAlexW3099277425

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.